Benjamin J. Lieblong

Clinical Trial Coordinator

University of Arkansas for Medical Sciences

staff

10 h-index 25 pubs 401 cited

Is this your profile? Verify and claim your profile

Biography and Research Information

OverviewAI-generated summary

Benjamin J. Lieblong's research focuses on therapeutic interventions for cervical intraepithelial neoplasia (CIN) and the immune response to vaccination and irradiation. He has investigated the expansion of human papillomavirus (HPV)-specific T cells in recipients of therapeutic vaccines, observing regression of high-grade squamous intraepithelial lesions. His work includes clinical trials evaluating peptide-based HPV therapeutic vaccines, such as PepCan, and their efficacy when combined with adjuvants like Candida, in treating CIN2/3.

Further research by Lieblong examines the influence of the kallikrein-kinin system on cardiac inflammation following local irradiation. He has a publication record of 25 articles, with a total of 401 citations and an h-index of 10. His collaborative network includes researchers from the University of Arkansas for Medical Sciences, such as Martin Hauer-Jensen and Vijayalakshmi Sridharan, with whom he has co-authored multiple publications.

Metrics

  • h-index: 10
  • Publications: 25
  • Citations: 401

Selected Publications

  • A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i> (2025) DOI
  • A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3). (2023) DOI
  • Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed (2021) DOI

Collaborators

Researchers in the database who share publications

Similar Researchers

Based on overlapping research topics